Dr David Lambeth is Professor of Pathology and Laboratory Medicine, and of Biochemistry at Emory University (Atlanta) and is founder of Theros Pharmaceuticals, Inc. He received his MD and PhD degrees from Duke University. After moving to Emory in 1980, his laboratory developed an interest in the enzymology of reactive oxygen generation in neutrophils. His lab has contributed extensively to the understanding the phagocyte NADPH oxidase and its regulation by protein-protein interactions. As a result of his interests in the origin of reactive oxygen generation in non-phagocytic cells, his laboratory reported the first homolog of the phagocyte oxidase, Nox1, in 1999. His laboratory has subsequently contributed extensively to the identification of novel NOX isoforms and their enzymatic and regulatory mechanisms.

 Dr. Lambeth's research focuses on reactive oxygen species (ROS) such as superoxide and hydrogen peroxide, and their biological roles, for example, in innate immunity, mitogenic growth, apoptosis, angiogenesis, and biosynthesis/remodeling of extracellular matrix.